Literature DB >> 11397986

[Idiopathic vitreomacular traction syndrome. Vitrectomy results].

H Rouhette1, P Gastaud.   

Abstract

PURPOSE: Evaluate the visual results, the complications and the prognosis factors of surgery for idiopathic vitreomacular traction syndrome.
METHODS: We retrospectly reviewed 29 consecutive eyes that had undergone pars plana vitrectomy and posterior epiretinal membrane peeling for idiopathic vitreomacular traction syndrome.
RESULTS: The mean follow-up after surgery was 17.7 months. Among the 29 cases, 21 were phakic. Visual acuity improved by 2 lignes or more in 72.4% of the cases and the mean improvement was 2.7. Eyes with preoperative visual acuity of 0.25 or more had better postoperative vision than the others (0.42vs0.65;p=0.006). During the follow-up, 10 patients underwent phacoemulsification and posterior chamber implantation (47.6%). The mean visual acuity of these 10 cases was poorer than the mean visual acuity of the 8 pseudophakic patients that underwent vitrectomy (0.45vs0.61;p=0.046). Five recurrences of epiretinal membrane were observed (17.2%).
CONCLUSIONS: Surgical treatment of vitreomacular traction syndrome improves visual acuity in most of cases. Further studies with optical coherence tomography are necessary to understand the pathogenic mechanisms of vitreomacular interface syndromes.

Entities:  

Mesh:

Year:  2001        PMID: 11397986

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  3 in total

1.  Epiretinal pathology of vitreomacular traction syndrome.

Authors:  A Gandorfer; M Rohleder; A Kampik
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

Review 2.  [OCT in epiretinal gliosis].

Authors:  A Hassenstein; F Scholz; G Richard
Journal:  Ophthalmologe       Date:  2005-02       Impact factor: 1.059

Review 3.  Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment.

Authors:  D H W Steel; A J Lotery
Journal:  Eye (Lond)       Date:  2013-10       Impact factor: 3.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.